Qumulo Launches New Pricing in AWS Marketplace
SEATTLE--(BUSINESS WIRE)-- Qumulo, Inc., a leader in data storage for hybrid cloud data management, today announced the availability of Pay-As-You-Go pricing for Cloud Native Qumulo (CNQ) in AWS Marketplace, a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy, and deploy software that runs on Amazon Web Services (AWS). This pricing removes key friction points for customers, allowing them to use CNQ immediately, with costs that scale dynamically with usage.
'Pay-As-You-Go lets CNQ customers subscribe instantly via AWS Marketplace and begin using the platform immediately. Customers can scale performance and capacity dynamically as their needs evolve, allowing them to start small with AWS and expand."
Share
'With Pay-As-You-Go CNQ, customers can subscribe instantly via AWS Marketplace and begin using the platform immediately,' said Qumulo CEO Doug Gourlay. 'Customers can scale performance and capacity dynamically as their needs evolve, allowing them to start small with AWS and expand without the need for upfront forecasting or lengthy procurement cycles.'
The new Pay-As-You-Go plan delivers flexible pricing and deployment for every customer. CNQ now offers two flexible consumption models:
Pay-As-You-Go (New) is ideal for customers evaluating cloud storage without committing to an upfront purchase. As organizations migrate data to the cloud, they can better assess costs based on actual usage.
Prepaid Credits are ideal for customers who want to align with a pre-budgeted procurement model or are happy to pre-pay in exchange for a discounted rate. Credits are consumed as the product is used, just like Pay-As-You-Go.
This dual-pricing model ensures that customers can choose the option that best aligns with their operational and financial goals. Key benefits of Pay-As-You-Go CNQ include:
Instant Deployment — Subscribe through AWS Marketplace and deploy CNQ in minutes.
Scalability Without Guesswork — No need to predict future storage requirements upfront. Customers can start small and expand their storage footprint over time.
Flexibility and Choice — Organizations can start with Pay-as-you-Go and migrate to Prepaid credits as required or stay on Pay-as-you-Go.
True Utility Pricing — Only pay for data stored or performance utilized by the minute with no need to provision either capacity or performance.
CNQ delivers best-in-class cloud storage capabilities because it was designed for demanding enterprise-grade workloads, including media & entertainment, life sciences, healthcare, and oil & gas. Customers benefit from:
Multi-protocol Access – NFS, SMB, and S3 support for hybrid and cloud-native workflows simplifies data and workload migration without application refactoring.
Optimized Performance & Cost —Hot and Cold storage modes, as well as performance options, allow organizations to optimize their storage platform to meet their workload needs.
Performance Without Compromise – High-speed NVMe SSD with Predictive Caching delivers low-latency, high-performance data access while drastically reducing API charges.
Enterprise Security & Compliance – Integrated encryption, snapshots, replication, Active Directory, and audit logging.
Availability
Cloud Native Qumulo (CNQ) Pay-As-You-Go is available now in AWS Marketplace. Pre-paid pricing remains available for volume-based discounts for enterprise customers with predictable workloads. Contact aws@qumulo.com for more information.
About Qumulo
Qumulo is the only seven-time Leader in the Gartner Magic Quadrant for Distributed File and Object Storage and the leading provider of cloud data platforms. With exabytes under management and more than 1,000 production customers, Qumulo empowers organizations to manage, store, curate, and protect their data, unlocking new possibilities and driving innovation across diverse industries. To learn more, visit www.qumulo.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Aeluma Inc trading resumes
13:06 EDT Aeluma (ALMU) Inc trading resumes Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yahoo
an hour ago
- Yahoo
Rakuten Medical Selected to Participate in FDA CEO Forum in San Diego
- Engaged with FDA Commissioner on shared commitment to fast, safe, and affordable patient access to innovative therapies SAN DIEGO, June 13, 2025 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was selected by the U.S. Food and Drug Administration (FDA) to participate in the FDA CEO Forum in San Diego, California, on June 13, 2025. Minami Maeda, President of Rakuten Medical, attended the meeting in person as a member of this panel, to discuss with FDA Commissioner Marty A. Makary, M.D., M.P.H., and other industry leaders how the FDA can "modernize its regulatory framework to better support innovation and patient access to safe and effective therapies". Rakuten Medical – whose innovative cancer therapeutic technology, the Alluminox™ platform, is in Phase 3 trials in the U. S. – was selected to join the forum as one of the companies at the front lines of medical discovery. Rakuten Medical's novel treatment modality, known as photoimmunotherapy, is designed to induce rapid and selective depletion of cancer or immunosuppressive cells with minimal impact on surrounding healthy tissue. Moreover, pre-clinical observation have shown that photoimmunotherapy may also stimulate both innate and adaptive anti-tumor immune responses. "Rakuten Medical's Alluminox™ platform has the potential to transform cancer therapy in the U.S.," said Maeda. "We are honored to be recognized by the FDA and invited to contribute to discussions on how regulatory innovation can accelerate the delivery of pioneering treatments to patients. We fully support the FDA's vision of a modern framework that ensures timely access, safety, and affordability." Rakuten Medical is currently conducting a global Phase 3 clinical trial evaluating its ASP-1929 photoimmunotherapy in combination with pembrolizumab as a first-line treatment for patients with recurrent head and neck squamous cell carcinoma (HNSCC) (Protocol number: ASP-1929-381 / Acronym: ECLIPSE / Identifier: NCT06699212). A prior Phase 1b/2 study showed promising interim evaluation results, including a 24-month survival rate of 52.4% and a median overall survival (OS) not yet reached. ASP-1929 photoimmunotherapy received the world's first regulatory approval in Japan under the Conditional Early Approval System based on a certain level of efficacy and acceptable safety from Phase 1/2a trial results. It is being delivered to patients in Japan at an affordable price. Disclaimer: Rakuten Medical's Alluminox™ platform-based photoimmunotherapy is investigational outside Japan. About Rakuten Medical, Inc. Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical's photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit About Alluminox™ platform The Alluminox™ platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical's pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical's Alluminox platform-based photoimmunotherapy is investigational. About ASP-1929Rakuten Medical's first pipeline drug developed on its Alluminox™ platform is ASP-1929, an antibody-dye conjugate comprised of the anti-EGFR antibody cetuximab and IRDye® 700DX, a light activatable dye. ASP-1929 binds to epidermal growth factor receptor (EGFR), a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority. Contact Us View original content to download multimedia: SOURCE Rakuten Medical, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Destiny Tech100 Inc. Reports First Quarter 2025 Results
NEW YORK, June 13, 2025--(BUSINESS WIRE)--Destiny Tech100 Inc. (NYSE: DXYZ) today announced financial results for the quarter ended March 31, 2025. The fund reported a net asset value (NAV) of $6.31 per share of common stock, from $6.44 per share at the end of the fourth quarter of 2024. As of March 31, 2025, Destiny Tech100's investment portfolio had an aggregate fair value of approximately $69.6 million, including short-term investments. The fund maintains positions in a variety of privately-held technology companies. Additional Information For more information about the Tech100 fund, Destiny XYZ Inc., the Fund's parent company, has made extensive resources available on its website. Prospective investors and the general public are encouraged to visit (in the Literature section) to receive the Fund's most recent annual report and other important information. About Destiny Tech100 Destiny Tech100 ("DXYZ" and "Tech100"), is a publicly-listed registered closed-end fund that intends to invest in a portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses. Destiny Tech100 Inc. is currently listed on the New York Stock Exchange under the ticker symbol "DXYZ." For a comprehensive list of holdings, visit the fund website at View source version on Contacts Robert Blecherpress@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
